SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia… Read more
SOLENO THERAPEUT. DL-001 (6XC) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SOLENO THERAPEUT. DL-001 - Net Assets Trend (None–None)
This chart illustrates how SOLENO THERAPEUT. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SOLENO THERAPEUT. DL-001 (None–None)
The table below shows the annual net assets of SOLENO THERAPEUT. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SOLENO THERAPEUT. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SOLENO THERAPEUT. DL-001 Competitors by Market Cap
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pitney Bowes Inc
NYSE:PBI
|
$1.56 Billion |
|
JEOL -JAPAN EL.OPT.-
F:JEL
|
$1.56 Billion |
|
Trump Media & Technology Group Corp.
NASDAQ:DJT
|
$1.56 Billion |
|
Yantai Moon Co Ltd
SHE:000811
|
$1.56 Billion |
|
Voltronic Power Technology Corp
TW:6409
|
$1.56 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
$1.56 Billion |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
$1.56 Billion |
|
Cairn Homes plc
PINK:CNHHY
|
$1.56 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SOLENO THERAPEUT. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SOLENO THERAPEUT. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SOLENO THERAPEUT. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SOLENO THERAPEUT. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SOLENO THERAPEUT. DL-001 (6XC) | €- | N/A | N/A | $1.56 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |